Boston University

Vivorx Pharmaceuticals, Inc.

Hyperbranch Medical Technology, Inc.

The Brigham and Women's Hospital, Inc.

Hydroglyde Coatings LLC

Boston Medical Center Corporation

University of California

Duke University

Beth Israel Deaconess Medical Center, Inc.

Centre National De La Recherche Scientifique

California Institute of Technology

The General Hospital Corporation

The Ohio State University

Fundacao Oswaldo Cruz

Affinergy Inc.

Mark W Grinstaff

Patrick Soon-Shiong

Neil P Desai

Kenneth S Suslick

Paul A Sandford

Benjamin Goldman Cooper

Yolonda Colson

Michael Wong

Keith R D'Alessio

Michael A Carnahan

Ruiqing Xiao

Stacy Lee Chin

Kenneth E Stockman

Michel Wathier

Jesse Wolinsky

Jonah Andrew Kaplan

Noma R Merideth

Solomon Azouz

Aaron Griset

Jack R Kirsch

Marlena Dagmara Konieczynska

Ara Nazarian

Edward Kenneth Rodriguez

Uros Kuzmanovic

James Galagan

Amanda K Williamson

Mingfu Chen

Thomas J Meade

Paul Theodore Hamilton

Harry B Gray

Ducksoo Kim

Scott Edward Schaus

Amit Meller

Nelson Ruiz-Opazo

Robin Hyde-DeRuyscher

Ray Edward Benson

Wilson W Wong

Dale J Christensen

Boris Nicolas Bloch

Eric M Bressler

Christopher Gromisch

Cynthia Ghobril

John A Kavouris

Lauren E Brown

Wilson Wai Chun Wong

Karen Nazaretian Allen

Catherine Klapperich

Daniel James Kenan

Aaron Henry Colby

Jonathan Robert Parquette

Victoria Herrera

Joseph Hersey

Shoeb I Khan

Allison Squires

Amy E Beilstein

Sarah Adams

Diana L Diaz

Danielle M Fitzgerald

James Mckerrow

Allison Dennis

Marjon Zamani

Camila Indiani De Oliveira

Samantha Berry

Aladin Hamoud

Brett Tingley

Joshua Edward Mcgee

Lidya Yidnekachew Sertse

Alina Ringaci

Jonah Kaplan

Iriny Ekladious

Anjeza Beharaj

Margaret Chern

Julia Wang

Jair Lage De Siqueira-neto

Thuy Nguyen

Chloe Grazon

Se Hye Kim

Philippe Barthelemy

Carla Prata

Karen Buch

Louis Moreau

William Blessing

Kexin Li

Heng Zhang

Orian Shirihai

Katherine Cook

Geoffrey S Hird

R Baer

Margarita Alexandrovna Tararina

Jialiu Zeng

Daniel J Kenan

Keith R D'alessio

Keith R D'ALESSIO

Wayne Fl Beyer

The inventions provided herein relate to injection applicators, tissue markers and uses thereof, e.g., to mark a target tissue site (e.g., a biopsy site in a breast tissue) or to produce a cell scaffold. The tissue markers described herein are designed to be resistant to fast migration (e.g., immediate migration after implantation through a needle track) and slow migration (e.g., over an extended period of time) upon implantation at a target tissue site (e.g., a biopsy site in a breast tissue), without using an adhesive. Additionally or alternatively, the tissue markers described herein can be readily detectable by at least one imaging modality, e.g., but not limited to magnetic resonance imaging, X-ray imaging, ultrasound imaging, or a combination thereof.

Injection applicator for tissue markers

Provided herein are novel polypeptides, methods for their production and uses thereof.

Polypeptides and uses thereof

Provided herein are antileishmanial compounds, compositions comprising the antileishmanial compounds, and use thereof.

Antileishmanial compounds, compositions and use thereof

The disclosure relates generally to methods and compositions for generation or enhancement of partial or complete cellular signaling pathways.

Synthetic cellular signaling pathways and uses thereof

The technology described herein is directed to compositions and methods for modifying and controlling the activity of cells by expression of proteins from self-amplifying RNA (saRNA). Also described herein are compositions and methods for modifying and controlling the activity of cells by expression of proteins from self-amplifying RNA that is substituted with chemically modified nucleotides.

Self-replicating RNA and uses thereof

The inventions provided herein relate to tissue markers and uses thereof, e.g., to mark a target tissue site (e.g., a biopsy site in a breast tissue) or to produce a cell scaffold. The tissue markers described herein are designed to be resistant to fast migration (e.g., immediate migration after implantation through a needle track) and slow migration (e.g., over an extended period of time) upon implantation at a target tissue site (e.g., a biopsy site in a breast tissue), without using an adhesive. Additionally or alternatively, the tissue markers described herein can be readily detectable by at least one imaging modality, e.g., but not limited to magnetic resonance imaging, X-ray imaging, ultrasound imaging, or a combination thereof.

Tissue markers and uses thereof

One aspect of the present invention generally relates to methods of sealing a wound or tissue plane or filling a void splace. In a preferred embodiment, the wound is an ophthalmic, pleural or dural wound. In certain instances, the compositions used to seal the wound or tissue plane comprises a polyalkyleneimine. In a preferred embodiment, the polyalkyleneimine is polyethyleneimine. Treatment of the polyethyleneimine with a cross-linking reagent causes the polyethyleneimine polymers to polymerize forming a seal. In certain instances, the cross-linking reagent is a polyethylene glycol having reactive terminal groups. In certain instances, the reactive terminal groups are activated esters, such as N-hydroxy succinimide ester. In certain instances, the reactive terminal groups are isocyanates. In certain instances, the polyethyleneimine has a lysine, cysteine, isocysteine or other nucleophilic group attached to the periphery of the polymer. In certain instances, the polyethyleneimine is mixed with a second polymer, such as a polyethylene glycol containing nucleophilic groups. In certain instances, the compositions used to seal the wound or tissue plane are formed by reacting a polyalkyleneimine bearing electrophilic groups with a cross-linking reagent containing nucleophilic groups. In certain instances, the electrophilic groups on the polyalkyleneimine are activated esters, such as N-hydroxy succinimide ester. In certain instances, the compositions used to seal the wound or tissue plane are formed by reacting a polyalkyleneimine bearing photopolymerizable groups with ultraviolet or visible light. Compositions used to seal the wound which contain PEI or a derivative of PEI are found to adhere tightly to the tissue. Other aspects of the present invention relate to methods of filling a void of a patient or adhering tissue. In certain instances, the methods use a polyalkyleneimine. In a preferred embodiment, the polyalkyleneimine is polyethyleneimine. Another aspect of the present invention relates to a polymeric composition formed by exposing a polyalkyleneimine to an activated polyalkylene glycol. In certain instances, the composition is attached to mammalian tissue.

Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices

The present disclosure generally relates to compositions and method for delivery, e.g., sustained delivery of active agents, and their use for the treatment of diseases or disorders.

Nanofiber scaffolds

The present invention provides methods for treating a stiffened joint in a subject that comprise administering relaxin, e.g., a PEGylated relaxin-2, to the subject. The relaxin may be administered intra-articularly as a sustained release formulation. The present invention also provides sustained release formulations in the form of a hydrogel for administering polypeptides that are covalently attached to a polymer, e.g., PEG.

Compositions comprising relaxin and methods of use thereof

The present invention provides formulations for the treatment of fibrotic diseases and disorders. In some embodiments, the formulation comprises a microparticle that includes an antifibrotic.

Formulations for treating a fibrotic disease

The invention provides polymer compositions, compounds, processes, and methods of use of the polymers for biodegradable consumer plastics, adhesives, e.g., bioadhesives, pressure sensitive adhesives and thermos-responsive adhesives.

Poly (alkyl carbonate) adhesives

Described herein are methods, compositions and processes related to a microbial-based biosensor system for the detection of small molecules and analytes based on an analyte-responsive transcription factor-DNA binding mechanism with either a ratiometric fluorescent output through F&#xf6;rster resonance energy transfer (FRET) or a redox sensor output for the quantification of the target analyte with high sensitivity.

Microbial-based biosensors

Described herein is an amperometric biosensor, e.g., chronoamperometric biosensor for the measurement of the concentration of nicotine. Also disclosed herein is a wearable nicotine biosensor device and a biosensor that detects nicotine in smoke. The biosensor disclosed herein comprises a nicotine-catalyzing enzyme, such as NicA2 or mutant NicA2 enzymes. Also described herein are systems comprising said amperometric biosensor, e.g., chronoamperometric biosensor and methods of using said chronoamperometric biosensor.

Enzyme-based electrochemical nicotine biosensor

The disclosure provides a drug delivery device that can release a drug or other molecule of interest in response to application of a mechanical force, such as tension, and methods of use thereof. The present disclosure provides a tension-responsive drug delivery device by exploiting a difference in mechanical properties between a drug-loaded core material and a supertiydrophobic barrier coating consisting of interconnected micro- and nano-sized particles formulated via the electrospraying of a mixture of biocompatible polymers.

Stretch release drug delivery materials

One aspect of the present invention generally relates to methods of sealing a wound or tissue plane or filling a void splace. In a preferred embodiment, the wound is an ophthalmic, pleural or dural wound. In certain instances, the compositions used to seal the wound or tissue plane comprises a polyalkyleneimine. In a preferred embodiment, the polyalkyleneimine is polyethyleneimine. Treatment of the polyethyleneimine with a cross-linking reagent causes the polyethyleneimine polymers to polymerize forming a seal. In certain instances, the cross-linking reagent is a polyethylene glycol having reactive terminal groups. In certain instances, the reactive terminal groups are activated esters, such as N-hydroxy succinimide ester. In certain instances, the reactive terminal groups are isocyanates. In certain instances, the polyethyleneimine has a lysine, cysteine, isocysteine or other nucleophilic group attached to the periphery of the polymer. In certain instances, the polyethyleneimine is mixed with a second polymer, such as a polyethylene glycol containing nucleophilic groups. In certain instances, the compositions used to seal the wound or tissue plane are formed by reacting a polyalkyleneimine bearing electrophilic groups with a cross-linking reagent containing nucleophilic groups. In certain instances, the electrophilic groups on the polyalkyleneimine are activated esters, such as N-hydroxy succinimide ester. In certain instances, the compositions used to seal the wound or tissue plane are formed by reacting a polyalkyleneimine bearing photopolymerizable groups with ultraviolet or visibile light. Compositions used to seal the wound which contain PEI or a derivative of PEI are found to adhere tightly to the tissue. Other aspects of the present invention relate to methods of filling a void of a patient or adhering tissue. In certain instances, the methods use a polyalkyleneimine. In a preferred embodiment, the polyalkyleneimine is polyethyleneimine. Another aspect of the present invention relates to a polymeric composition formed by exposing a polyalkyleneimine to an activated polyalkylene glycol. In certain instances, the composition is attached to mammalian tissue.

Growing community of inventors

Brookline, MA, United States of America

Mark W Grinstaff